# Thyrocare Technologies (NSE: THYROCARE) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/THYROCARE · Pivot · prices to 22 Oct 2026

Thyrocare Technologies (NSE: THYROCARE) closed at ₹470.65 on 22 Oct 2026, up 3.44% on the day. With a market capitalisation of ₹7,491 Cr, it ranks 641st by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Diagnostics & Research.

At its last close the stock traded at 46.2× trailing earnings, against a return on equity of 27.8% in FY26. Over the past year the share price has risen 11.6%. Its 52-week range is ₹342.55 (23 Mar 2026) to ₹662.00 (12 Aug 2026); the last close is 28.9% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹240 Cr (+24.3% year on year) and net profit ₹51 Cr (+33.1%), on a consolidated basis. Promoters held 60.92% of the company as of 30 Jun 2026; 100.00% of promoter shares were pledged.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹470.65 |
| Market cap | ₹7,491 Cr |
| P/E (trailing) | 46.2 |
| ROE | 27.8% (FY26) |
| ROCE | 34.6% (FY26) |
| Debt to equity | 0 |
| 52-week high | ₹662.00 (12 Aug 2026) |
| 52-week low | ₹342.55 (23 Mar 2026) |
| 1-year return | +11.6% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹240 Cr | +24.3% | ₹51 Cr | +33.1% | ₹3.23 |
| Q4 FY26 | ₹224 Cr | +19.7% | ₹48 Cr | +116.8% | ₹2.99 |
| Q3 FY26 | ₹196 Cr | +17.8% | ₹28 Cr | +45.3% | ₹1.82 |
| Q2 FY26 | ₹217 Cr | +22.1% | ₹48 Cr | +77.9% | ₹9.05 |
| Q1 FY26 | ₹193 Cr | +23.0% | ₹38 Cr | +56.5% | ₹7.35 |
| Q4 FY25 | ₹187 Cr | +21.3% | ₹22 Cr | +27.6% | ₹4.17 |
| Q3 FY25 | ₹166 Cr | +23.1% | ₹19 Cr | +30.8% | ₹3.58 |
| Q2 FY25 | ₹177 Cr | +19.8% | ₹27 Cr | +33.8% | ₹4.99 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY26 | ₹4 Cr | ₹0 Cr |
| FY25 | ₹6 Cr | −₹0 Cr |
| FY24 | ₹5 Cr | −₹0 Cr |
| FY23 | ₹8 Cr | ₹0 Cr |
| FY22 | ₹10 Cr | ₹1 Cr |
| FY21 | ₹6 Cr | ₹0 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 60.92%
- Foreign institutions: 5.44%
- Domestic institutions: 20.92%
- Non-institutions: 12.72%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Suven Life Sciences](https://app.pivotnow.in/stock/SUVEN) | ₹276.60 | ₹7,816 Cr | — | — |
| [Sanofi Consumer Healthcare India](https://app.pivotnow.in/stock/SANOFICONR) | ₹3,325.80 | ₹7,660 Cr | 29.7 | — |
| [Aarti Pharmalabs](https://app.pivotnow.in/stock/AARTIPHARM) | ₹838.00 | ₹7,599 Cr | 43.6 | — |
| [Morepen Laboratories](https://app.pivotnow.in/stock/MOREPENLAB) | ₹125.70 | ₹6,888 Cr | 72.7 | — |
| [Supriya Lifescience](https://app.pivotnow.in/stock/SUPRIYA) | ₹848.80 | ₹6,831 Cr | 32.7 | — |
| [Bliss GVS Pharma](https://app.pivotnow.in/stock/BLISSGVS) | ₹638.00 | ₹6,766 Cr | 53.1 | — |

## Questions and answers

### What is the share price of Thyrocare Technologies today?

Thyrocare Technologies (NSE: THYROCARE) last closed at ₹470.65 on 22 Oct 2026. Its 52-week high is ₹662.00 and its 52-week low is ₹342.55.

### What is the market cap of Thyrocare Technologies?

Thyrocare Technologies' market capitalisation is ₹7,491 Cr (₹7,491 Cr) at the 22 Oct 2026 close, ranking 641st among the NSE companies Pivot tracks.

### What is the P/E ratio of Thyrocare Technologies?

Thyrocare Technologies trades at a trailing P/E of 46.2. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 43.6.

### What is the ROE and ROCE of Thyrocare Technologies?

Return on equity was 27.8% in FY26 and return on capital employed was 34.6% in FY26 (consolidated figures).

### Is Thyrocare Technologies a debt-free company?

Thyrocare Technologies is close to debt-free: its debt-to-equity ratio was 0 in FY26.

### What were Thyrocare Technologies' latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), Thyrocare Technologies reported revenue of ₹240 Cr, +24.3% year on year, and net profit of ₹51 Cr, +33.1% year on year.

### How has Thyrocare Technologies stock performed over the last year?

Thyrocare Technologies' share price has risen 11.6% over the past year, −15.5% over three months and −17.7% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Thyrocare Technologies?

As of 30 Jun 2026: promoters 60.92%, foreign institutions 5.44%, domestic institutions 20.92%, non-institutions 12.72%. 100.00% of promoter shares were pledged.

### Who are Thyrocare Technologies' competitors?

The listed Pharma & Healthcare companies closest to Thyrocare Technologies by market cap are Suven Life Sciences, Sanofi Consumer Healthcare India, Aarti Pharmalabs, Morepen Laboratories, Supriya Lifescience and Bliss GVS Pharma.

### Is Thyrocare Technologies a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Thyrocare Technologies' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on THYROCARE against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.